Quick Answer
Unicycive Therapeutics, Inc. reported Total Revenue of $675.0 thousand for fiscal year 2023.
Unicycive Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $675.0K -29.0% |
$951.0K | — | — |
| Net Income | -$26.55M +27.7% |
-$36.73M -20.2% |
-$30.54M -69.1% |
-$18.06M -80.3% |
-$10.02M -342.4% |
-$2.26M |
| Diluted EPS | -$1.67 +70.4% |
-$5.65 -341.4% |
-$1.28 -6.7% |
-$1.20 -39.5% |
-$0.86 | — |
| Total Assets | $49.13M +55.2% |
$31.67M +123.2% |
$14.19M +403.6% |
$2.82M -85.0% |
$18.74M +9088.2% |
$204.0K |
| Cash and Equivalents | $29.20M +11.7% |
$26.14M | — | $455.0K -97.3% |
$16.58M | — |
| Stockholders Equity | $30.20M +306.4% |
$7.43M +295.1% |
-$3.81M -717.4% |
-$466.0K -102.8% |
$16.48M +717.1% |
-$2.67M -202.1% |
| R&D Expense | $9.12M -54.4% |
$20.01M +55.1% |
$12.90M +3.7% |
$12.44M +104.5% |
$6.08M +499.0% |
$1.01M |
| Operating Income | -$29.52M +8.1% |
-$32.12M -54.6% |
-$20.77M -15.1% |
-$18.05M -101.1% |
-$8.98M -344.4% |
-$2.02M |
| Shares Outstanding | 22.11M +94.3% |
11.38M -67.2% |
34.76M +128.2% |
15.23M +1.6% |
15.00M +76.1% |
8.51M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2023 | $675.0K | — | -29.0% |
| Net Income | September 30, 2025 | -$6.01M | -46.8% | +6.8% |
| Diluted EPS | September 30, 2025 | -$0.33 | +28.3% | +36.5% |
| Total Assets | September 30, 2025 | $50.61M | +31.2% | +68.7% |
| Cash and Equivalents | September 30, 2025 | $42.70M | — | +91.2% |
| Stockholders Equity | September 30, 2025 | $37.48M | +234.6% | +128.1% |
| R&D Expense | September 30, 2025 | $2.96M | -2.7% | +69.4% |
| Operating Income | September 30, 2025 | -$7.34M | -17.5% | -5.4% |
| Shares Outstanding | September 30, 2025 | 20.85M | -78.7% | +47.8% |
- Unicycive Therapeutics, Inc. reported Total Revenue of $675.0 thousand for fiscal year 2023.
- Unicycive Therapeutics, Inc. showed a decrease of -29.0% in Total Revenue compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported Net Income of -$26.55 million for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed an increase of +27.7% in Net Income compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported Diluted EPS of $1.67 per share (loss) for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed an increase of +70.4% in Diluted EPS compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported Total Assets of $49.13 million for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed an increase of +55.2% in Total Assets compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported Cash and Equivalents of $29.20 million for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed an increase of +11.7% in Cash and Equivalents compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported Stockholders Equity of $30.20 million for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed an increase of +306.4% in Stockholders Equity compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported R&D Expense of $9.12 million for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed a decrease of -54.4% in R&D Expense compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported Operating Income of -$29.52 million for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed an increase of +8.1% in Operating Income compared to the prior fiscal year.
- Unicycive Therapeutics, Inc. reported Shares Outstanding of 22.11 million shares for fiscal year 2025.
- Unicycive Therapeutics, Inc. showed an increase of +94.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: